Overview

A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

Status:
RECRUITING

Trial end date:
2029-02-23

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease

Phase:

PHASE3

Details

Lead Sponsor:

Bristol-Myers Squibb